Zydus Of India, Teva Of Israel Settle Two Generics Disputes
This article was originally published in PharmAsia News
Executive SummaryIndia's ZydusCadila and Israel's Teva have reached a settlement of generics makers over a patent dispute involving the active pharmaceutical ingredients of multinational company antipsychotic drugs. Zydus and Teva had squabbled over competing generics to be marketed in the United States, but the settlement allows Zydus to sell its versions without facing a legal challenge by Teva. The API at issue is carvedilol, used in GlaxoSmithKline's Coreg, which lost its patent protection last year. Zydus had sued Teva over a generic of Johnson & Johnson's Risperdol (risperidone), accusing the Israeli company of antitrust and deceptive filings with the U.S. Patent and Trademark Office. (Click here for more
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.